What actually happens, week by week.
Timeline expectations are the most-gamed number in this market. Before/after marketing compresses a year into two photos; the trial curves tell a slower, more honest story. Here is what the data actually says to expect — and when no-response is itself the answer.
The short version: the honest timeline for GLP-class compounds is measured in months. The trials behind the headline numbers ran 48 to 72 weeks — STEP 1 reported roughly 14.9% average weight loss with semaglutide at 68 weeks, SURMOUNT-1 roughly 20.9% with tirzepatide at 72 weeks, and the retatrutide phase 2 roughly 24% at 48 weeks — and in every one of them the first weeks were low-dose titration, not results. Healing peptides have no human timeline data at all. GH-axis markers move in weeks; body composition moves far slower. Anyone promising a transformation on a calendar shorter than the trials ran is selling the calendar, not the compound.
- Trial headline numbers took 48–72 weeks to produce. A marketing timeline shorter than the trial that generated the number is a red flag by arithmetic alone.
- The first weeks on a GLP-class compound are titration by design — low dose, GI adjustment, modest change. The curves diverge meaningfully over months.
- Healing peptides have no human timeline data. Every "feel it in two weeks" claim for BPC-157-class compounds traces to animal models or anecdote, not human trials.
- GH-axis peptides move lab markers before they move mirrors. IGF-1 changes are measurable within weeks in studies; body-composition shifts take far longer.
- Plateaus are in the trial curves too. Weight-loss trajectories flatten toward a new steady state — that is the pharmacology, not a product defect.
- Non-response is a real, documented outcome. When nothing measurable happens across a reasonable window, stopping is rational — and with gray-market product, a dead vial is always on the suspect list.
Why timelines are the most-gamed number in the market
Every other number a vendor can game — purity, fill, testing claims — lives on a document you can check. The timeline lives in your expectations, which makes it the cheapest number to inflate. Before/after imagery is the standard instrument: two photos, an implied duration, no dosing history, no failure cases. The trial literature is the counterweight, because a registered trial cannot compress its own calendar. When STEP 1 reports its result at week 68, week 68 is what the result cost.
So the most useful habit this page can give you is a single reflex: when you see a claimed result, ask what week the supporting data was measured at. If the answer is "week 60-something" and the marketing implies month two, you have learned what the marketing is worth.
The GLP class: the honest shape of the curve
The GLP-class weight-loss compounds — semaglutide, tirzepatide, and the still-unapproved retatrutide — have the best timeline data in the entire peptide market, because they ran large randomized trials with published week-by-week curves. Three anchors define the class:
- Semaglutide — STEP 1 reported roughly 14.9% average weight loss at 68 weeks in adults with overweight or obesity, against roughly 2.4% on placebo. GI side effects were the most common adverse events.
- Tirzepatide — SURMOUNT-1 reported roughly 20.9% average loss at the highest dose at 72 weeks.
- Retatrutide — the phase 2 trial reported roughly 24% average loss at the highest dose at 48 weeks. It remains unapproved, with phase 3 still running.
Two structural facts matter more than the headline percentages. First, every trial escalated dose stepwise over months — participants spent the opening weeks at a fraction of the maintenance dose, because the GI side effects that dominate this class are dose-dependent and worst during escalation. Second, the loss curves are gradual and roughly steady for most of the trial, flattening toward the end. There is no cliff where the weight falls off; there is a slope, gated by titration at the front and a plateau at the back.
Weeks 1–4, 5–12, 13 and beyond
The table below is descriptive, drawn from how the GLP-class trials were structured — it is what the protocols did and what the published curves show, not a protocol for anyone to follow.
| phase | what the trials were doing | what the curves show |
|---|---|---|
| weeks 1–4 | Starting dose, deliberately sub-therapeutic. First escalation steps begin. | Appetite effects arrive early for many participants; measured weight change is modest. GI adjustment — nausea most commonly — is at its worst during these escalation weeks. |
| weeks 5–12 | Stepwise escalation continues toward the maintenance dose. | The treatment and placebo curves separate clearly. Loss accumulates at a steady rate rather than in jumps. |
| weeks 13+ | Participants reach and hold the maintenance dose. | The slope continues for months, then flattens toward a plateau. The headline numbers sit at week 48, 68, or 72 — the far end of this phase, not the start of it. |
Read that last row twice. The gap between week 13 and week 68 is where most of the published result lives, and it is precisely the stretch that before/after marketing edits out.
Healing peptides: there is no human timeline
Here the honest answer is short. For BPC-157 and the rest of the healing-and-repair category, there is no human trial database from which to draw a timeline at all. The two-week and four-week recovery windows that circulate in forums trace back to animal models — rodent tendon transection studies, gut lesion models — or to anecdote.
What animal timescales do tell you: in those models, measurable effects on healing markers appeared across days-to-weeks study windows. What they do not tell you: whether the effect exists in humans, at what dose, by what route, or on what calendar. Rodents heal faster than humans at baseline, the injury models are surgical and standardized in a way real injuries are not, and dosing was proportionally different. Translating "the rats improved by day 14" into "your tendon improves by week two" is not extrapolation — it is fiction with a citation. Our BPC-157 evidence review grades this literature in full.
GH-axis peptides: markers move first, mirrors move later
The growth-hormone-axis compounds — GHRH analogs and secretagogues — have a split timeline worth understanding. In published studies of the approved GHRH analog tesamorelin, IGF-1 changes are measurable within weeks — the axis responds quickly, and blood work shows it. Body composition is the slow half: the visceral-fat reductions in the tesamorelin trials were measured over months of continuous use, and lean-mass changes across this class are slower and smaller than marketing implies.
The practical reading: with GH-axis compounds, weeks-scale expectations belong to lab markers, and months-scale expectations belong to anything you can see. A vendor pitching visible recomposition in a month is quoting the fast half of the timeline against the slow half of the outcome.
Skin and cosmetic peptides: remodeling runs on biology's clock
Collagen remodeling — the mechanism behind GHK-Cu and the cosmetic-peptide category — operates on multi-week-to-month cycles regardless of what is applied or injected. Skin turnover runs roughly a month per cycle, and dermal collagen synthesis and reorganization run longer. The published studies on copper peptides measured changes across multi-week and multi-month windows, consistent with that biology. Overnight-glow claims are describing hydration and surface effects, not remodeling; the remodeling story, where it exists, is a months story.
The plateau conversation
Every GLP-class trial curve flattens. Weight loss decelerates and settles toward a new steady state — the body adapts, energy expenditure shifts, and the compound's effect reaches equilibrium with it. This is worth internalizing before month six rather than after: the plateau is in the data. It is not evidence of a bad batch, a tolerance crisis, or a need to escalate past studied doses. In the trials, the plateau is simply what the far end of the curve looks like. Market behavior at the plateau — stacking a second compound, pushing dose — is exactly the point where people leave the evidence base entirely, and worth reading alongside our side-effects fundamentals.
When no-response is the answer
Trial datasets are averages wrapped around a distribution, and the low tail is real: some participants in every GLP trial lost far less than the mean, on pharmaceutical-grade product with verified dosing. Non-response exists even when everything is exactly what it says it is.
In the research-compound market a second explanation always sits alongside it: the vial. Underdosed, degraded, or misidentified product produces the same nothing that biological non-response does — and without testing, the two are indistinguishable from the inside. A verifiable certificate narrows the suspect list; it never empties it.
Either way, the rational reading is the same. When a window comparable to the relevant data — months for the GLP class, honestly undefined for compounds with no human data — has passed with nothing measurable, continuing to spend money on the same nothing is not persistence. Stopping is what the evidence supports, and in a market this fond of "give it more time," that sentence is the one nobody selling anything will say.
FAQ
How long did the major GLP-1 weight-loss trials run?
STEP 1 reported its semaglutide result at 68 weeks, SURMOUNT-1 reported tirzepatide at 72 weeks, and the retatrutide phase 2 reported at 48 weeks. Those durations are part of the result — the headline percentages do not exist at earlier timepoints.
Why is week one so unimpressive?
Because trial protocols made it that way on purpose. Starting doses were deliberately low and escalated stepwise over months to manage dose-dependent GI effects. The opening weeks combine a sub-therapeutic dose with the roughest adjustment period — the least representative stretch of the whole curve.
Is there a real timeline for BPC-157 or other healing peptides?
No human one. The circulating timelines come from animal models and anecdote. Animal studies show effects within their own short windows, but species, dose, route, and injury model all differ — no human recovery calendar can honestly be derived from them.
What if I see nothing at all?
Both explanations deserve the same weight: non-response is documented in every trial, and unverified product can be underdosed or misidentified. After a reasonable window with no measurable change, the evidence supports stopping — not escalating past studied doses.
References & further reading
- Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity [STEP 1], N Engl J Med 2021 — nejm.org
- Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1], N Engl J Med 2022 — nejm.org
- Jastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — phase 2, N Engl J Med 2023 — nejm.org
- Our compound-level evidence reviews — retatrutide, graded · BPC-157, graded honestly
disclosure: inside your peptides may earn referral fees from vendor links elsewhere on this site — none appear on this page. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.